Michael J. Ricciardi
Chief Commercial Officer
Dr. Ricciardi is the Associate Director of Translational Research at George Washington University in Washington DC, Director of Product Development at Mabloc, LLC, and President of Miami Medical Consulting Corp. Dr. Ricciardi is responsible for leading both the discovery and development of research and commercial products from the laboratory bench to the patient’s bedside.
My interests focus on the role of monoclonal antibodies (mAbs) and their ability to treat and diagnose a variety of diseases including Dengue, Zika, Yellow fever, Coronaviruses, Influenza, Herpes, HIV, and others. Over the past decade, mAbs have become one of the most popular classes of medications due to their incredible specificity and tolerability. Recent technological advances in mAb development, including single cell cloning, next-generation sequencing, and rapid screening has had an enormous impact on the development of these drugs. With these advances, I have been able to pair recombinant viral vectors technology with newly developed molecular biology tools and immunology techniques to come up with the Broadly Reactive Antibody Isolation and Development (BRAID) platform. The BRAID platform has allowed our small research team to isolate and develop mAbs faster, cheaper, and on a larger scale than ever before. This allows us to discover mAbs against diseases that are often overlooked and provide critical, life changing medicines to people all around the world.